Shares of Vaxcyte Inc.
soared 22% in their trading debut Friday, after the company's IPO priced at the top end of its price range, and was upsized to 15.6 million shares from earlier plans to sell just 14 million. The company raised $249.6 million. The shares are trading on Nasdaq later Friday under the ticker symbol"PCVX." BofA Securities, Jefferies and Evercore ISI were lead underwriters on the deal with Cantor and Needham acting as co-managers.
Sheer speculation. As is much of stock market right now. And protected by the Fed.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: